Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14844388 | 0.71 | TSHR (0.37) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL6215102 | 0.69 | KDM4E (0.68) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL15414899 | 0.69 | TRPM8 (0.39) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL19250267 | 0.67 | NR3C2 (0.39) | MEN1KMT2AGAA | |
| SCHEMBL11407980 | 0.67 | MEN1 (0.65) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL22496048 | 0.66 | TSHR (0.38) | ALDH1A1SMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL27629277 | 0.66 | NPC1 (0.54) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL1690729 | 0.66 | RAB9A (0.50) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL3846783 | 0.66 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL11115599 | 0.66 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728240-B1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11180488-B2 | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL MYERS SQUIBB CO (US) | 2021-11-23 | — | — | US | disclosed |
| CN-112041316-A | Isoxazole O-linked carbamoylcyclohexanoic acids as LPA antagonists | 百时美施贵宝公司 | 2020-12-04 | — | — | CN | disclosed |
| EP-3728240-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200317655-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317655-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR4, LPAR6 | ALDH1A1 3219/4885SMN1; SMN2 4501/4885NPC1 846/4885 |
| US-11180488-B2 | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR6, LPAR4 | ALDH1A1 3220/4885SMN1; SMN2 4473/4885NPC1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.